South African Medical News

Back to Home Page

Print using browser
CONCOMITANT FLUOROQUINOLONES AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEIs) / ANGIOTENSIN RECEPTOR BLOCKERS USE

Dear Healthcare Professional

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the below listed companies would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with ACE inhibitors / Angiotensin Receptor Blockers (ARBs) and fluoroquinolones.

Activo Health (Pty) Ltd, Austell Laboratories (Pty) Ltd, Camox Pharmaceuticals (Pty) Ltd, Dezzo Trading 392 (Pty) Ltd, Hetero Drugs SA Pty Ltd, Litha Pharma (Pty) Ltd, Macleods Pharmaceuticals SA, Mylan (Pty) Ltd, Xixia Pharmaceuticals (Pty) Ltd (a Mylan Company), Pharmaceutical Contractors (Pty) Ltd, Pharmaplan (Pty) Ltd, Specpharm (Pty) Ltd, Trinity Pharma, Unicorn Pharmaceuticals (Pty) Ltd.

You need to be logged in to see more details. Register Now!



Contact: As per the document
Telephone:
E-mail: As per the document
Date: Friday, October 4, 2019